What is Cybergenetics?
Cybergenetics stands as a pioneer in the field of advanced DNA software, with a legacy spanning over 25 years. The company is best known for its TrueAllele technology, a sophisticated probabilistic genotyping platform that converts complex, uninterpretable forensic evidence into definitive identification data. Beyond its core forensic applications, the firm has expanded its footprint into the retail sector with ORCA, a specialized DNA intelligence platform designed to mitigate retail theft through rapid crime scene analysis. By bridging the gap between complex genomic data and actionable intelligence, Cybergenetics serves a diverse clientele ranging from law enforcement agencies to medical research institutions, effectively setting the industry standard for automated DNA analysis.
How much funding has Cybergenetics raised?
Cybergenetics has raised a total of $300K across 2 funding rounds:
Debt
$150K
Debt
$150K
Debt (2020): $150K with participation from PPP
Debt (2021): $150K led by PPP
Key Investors in Cybergenetics
PPP
Public-Private Partnership
What's next for Cybergenetics?
With this recent capital, Cybergenetics is poised to accelerate its growth trajectory by enhancing its software-as-a-service capabilities and expanding the reach of its DNA intelligence platforms. The strategic focus will likely center on deepening the integration of TrueAllele within international judicial systems and scaling the ORCA platform to address the rising demand for forensic-grade loss prevention tools. As the company transitions through this late-stage growth phase, the emphasis remains on maintaining technical superiority while navigating the evolving regulatory landscape of forensic genomics. Future initiatives will likely prioritize the automation of complex data pipelines, ensuring that Cybergenetics remains at the forefront of the intersection between biotechnology and public safety.
See full Cybergenetics company page
